← All trials
NCT04390061
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Sep 30, 2020
- Completion date
- Oct 31, 2020
- First posted
- May 15, 2020
- Last posted
- May 15, 2020
- Enrollment
- 116
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Marche Polytechnic UniversityLead sponsor
- Ospedale di CircoloCollaborator
- Marche Polytechnic UniversityCollaborator
- Marche Polytechnic UniversityReponsible party - principal investigator
- Azienda Ospedaliera Istituti Ospitalieri CremonaCollaborator
- A.O. Ospedale Papa Giovanni XXIIICollaborator
- Ospedale Umberto I di TorinoCollaborator
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoCollaborator
- Ospedale Civile Santo Spirito, PescaraCollaborator
- Magna Graecia UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.